| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5623554 | Alzheimer's & Dementia | 2007 | 5 Pages |
The overall goal of value therapy is to provide the most efficient use of resources, taking into account both the cost and the value derived from a given technology or drug, and to assist in healthcare decision-making, because both cost and effectiveness are considered. After a short review of European Medicines Agency (EMEA) Committee for Medicinal Products for Human Use (CHMP) recommendations for the development of medications for Alzheimer's disease, we focus on the evidence with respect to cost and benefits obtained so far with acetylcholinesterase inhibitor (AChEI) and Memantine in the treatment of Alzheimer's disease. We then analyze the recommendations developed by professionals for the treatment of Alzheimer's disease at the national level in European countries, and finally we discuss how to utilize this process more homogenously in the future to assess value therapeutic values in Alzheimer's disease.
